Live Breaking News & Updates on Rheumatology franchise

The Psoriatic Arthritis Landscape Continues to Evolve as New Launches Alter Dynamics in Both US and EU Markets, Spherix Reports

/PRNewswire/ TNF inhibitors continue to be the mainstay for treating psoriatic arthritis (PsA), largely driven by the gold standards, etanercept and.

Germany , Italy , United-kingdom , France , Spain , Novarti-cosentyx , Eli-lilly-taltz , Abbvie-rinvoq , Maxine-yarnall , Abbvie-skyrizi , Janssen-tremfya ,

The Psoriatic Arthritis Landscape Continues to Evolve as New Launches Alter Dynamics in Both US and EU Markets, Spherix Reports

/PRNewswire/ TNF inhibitors continue to be the mainstay for treating psoriatic arthritis (PsA), largely driven by the gold standards, etanercept and.

Germany , Italy , United-kingdom , France , Spain , Novarti-cosentyx , Eli-lilly-taltz , Abbvie-rinvoq , Maxine-yarnall , Abbvie-skyrizi , Janssen-tremfya ,

Spherix Research Reveals Rheumatologists Taking the Lead Over Nephrologists in Both BENLYSTA (GlaxoSmithKline) and LUPKYNIS (Aurinia) Patient Initiations in Lupus Nephritis

/PRNewswire/ With the approvals of GlaxoSmithKline s Benlysta in lupus nephritis (LN) at the end of 2020 and Aurinia s Lupkynis at the beginning of 2021,.

Novartis-cosentyx , Roche-genentech-gazyva , Chemocentryx-tavneos , Maxine-yarnall , Aurinia-lupkynis , Glaxosmithkline-benlysta , Janssen-tremfya , Our-services , Dynamix , Launch-dynamix , Global-insights , Rheumatology-franchise

Novartis' Cosentyx and Eli Lilly's Taltz Remain Leaders in US and EU5 Psoriatic Arthritis Switching Market, but Janssen's Tremfya and AbbVie's Skyrizi Are Picking Up Steam, Spherix Reports

/PRNewswire/ Spherix Global Insights, a leading market intelligence firm specializing in immunology-based research and insights, recently published several.

Germany , Italy , United-states , United-kingdom , France , Spain , Abbvie-rinvoq , Maxine-yarnall , Abbvie-skyrizi , Janssen-stelara , Janssen-tremfya , Gianna-melendez